MOLOGEN AG has three unique platform technologies in the field of immunotherapies and beyond that offer a  wide range of possible applications. These technology platforms also form the basis for the first highly promising medicines that are currently in various stages of research and clinical development.

1) DNA-based TLR9 agonists (dSLIM® (Lefitolimod) and EnanDIM®)- With its dSLIM® DNA molecule, MOLOGEN has created a modern tool capable of exerting a specific influence on the patient's immune system (a process known as immunomodulation). Of note is the fact that this immunomodulator is extremely versatile and can be used for a variety of possible applications in the field of cancer treatments and potentially also in the field of infectious diseases. It can also be used as an enhancer (or adjuvant) in combination with other treatment approaches or drugs.

EnanDIM® - (Enantiomeric, DNA-based, ImmunoModulator) represents a new generation of immunomodulators. It is in the pre-clinical development stage and promises to deliver broad immuneoactivation. EnanDIM® has the potential to be used in various cancer indications either as monotherapy, in combination with other targeted therapies or immune modulators, such as so called checkpoint inhibitors, or with other immunotherapeutic approaches. It could also potentially be used in the field of infectious diseases.

Development activities concentrate on this of the three MOLOGEN-proprietary plattforms. The ability to market the compounds, especially lefitolimod, is substantially strengthened.

2) Non-viral MIDGE® vector system - With our development of the MIDGE® vector system, we have created the basis for a broad spectrum of modern, DNA-based applications. The vectors can be equipped with various customized genetic information. This makes them ideal both for the genetic modification of tumor cells in the context of cell-based gene therapy against cancer as well as for DNA-based vaccinations against infectious diseases. The vectors can be used for prophylactic and therapeutic vaccinations.

MIDGE® currently comprises three drug candidates. Due to limited financial resources and the focus on lefitolimod, it is not possible to substantially progress these projects. Consequently, MOLOGEN intends to sell off the technology together with all the associated compounds; a spin-off is conceivable as an alternative.

3) Allogeneic tumor cell bank - The tumor cell line established by MOLOGEN offers a unique platform for cell-based therapy against cancer. The tumor cell line has been established as a cell bank in accordance with drug law specifications. The cells can be genetically modified using MIDGE® vectors, thereby adapting them to their intended purpose.

Further development of the cell-based therapeutic vaccine MGN1601 against renal cancer, is to be shelved for the time being. However, development will be continued if lefitolimod is successfully out-licensed.